112566-20-8 | Imidazo[1,2-a]pyridin-2-ol

Packsize	Purity	Availability	Price	Discounted Price
250mg	95%	in stock	$23.00	$16.00
1g	95%	in stock	$50.00	$35.00
5g	95%	in stock	$152.00	$106.00
10g	95%	in stock	$253.00	$177.00

Description

• Catalog Number: AE22638
• Chemical Name: Imidazo[1,2-a]pyridin-2-ol
• CAS Number: 112566-20-8
• Molecular Formula: C7H6N2O
• Molecular Weight: 134.1353
• MDL Number: MFCD09994219
• SMILES: Oc1nc2n(c1)cccc2

Computed Properties

• Complexity: 129
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 10
• Hydrogen Bond Acceptor Count: 2
• Hydrogen Bond Donor Count: 1
• XLogP3: 1.7

Upstream Synthesis Route

Imidazo[1,2-a]pyridin-2-ol is a versatile compound commonly used in chemical synthesis for its unique structural properties. This compound serves as a valuable building block in the development of various organic molecules due to its potential to participate in diverse chemical reactions.One of the key applications of Imidazo[1,2-a]pyridin-2-ol in chemical synthesis is its role as a heterocyclic scaffold in the design and synthesis of pharmaceuticals. By incorporating Imidazo[1,2-a]pyridin-2-ol into the molecular structure of drug candidates, chemists can potentially enhance the biological activity, solubility, and metabolic stability of the resulting compounds.Furthermore, Imidazo[1,2-a]pyridin-2-ol can be utilized as a key intermediate in the preparation of various functionalized heterocycles. Its reactivity towards a range of electrophiles and nucleophiles allows for the introduction of different substituents onto the imidazo ring, enabling the synthesis of diverse chemical entities with specific properties and functionalities.Additionally, Imidazo[1,2-a]pyridin-2-ol can be employed in the construction of natural product analogs and molecular probes for biological studies. Its adaptable structure and synthetic accessibility make it a valuable tool for organic chemists seeking to create novel compounds for medicinal chemistry and chemical biology research.In summary, Imidazo[1,2-a]pyridin-2-ol plays a crucial role in chemical synthesis as a versatile building block for the preparation of pharmaceuticals, heterocyclic compounds, and molecular probes. Its unique structural features and reactivity make it a valuable asset in the toolkit of synthetic chemists working towards the development of new chemical entities for various applications.

Literature

• Effects of ZSET1446/ST101 on cognitive deficits and amyloid β deposition in the senescence accelerated prone mouse brain.

  Journal of pharmacological sciences 20120101

• ST101 induces a novel 17 kDa APP cleavage that precludes Aβ generation in vivo.

  Annals of neurology 20110501

• [Neurochemical mechanisms of a novel Alzheimer's disease therapeutics on improvement of cognition and depressive behavior].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20110401

• Pharmacologic Treatment with GABA(B) Receptor Agonist of Methamphetamine-Induced Cognitive Impairment in Mice.

  Current neuropharmacology 20110301

• A humanin derivative reduces amyloid beta accumulation and ameliorates memory deficit in triple transgenic mice.

  PloS one 20110101

• Potential Antidepressant Role of Neurotransmitter CART: Implications for Mental Disorders.

  Depression research and treatment 20110101

• A novel azaindolizinone derivative ZSET1446 (spiro[imidazo[1,2-a]pyridine-3,2-indan]-2(3H)-one) improves methamphetamine-induced impairment of recognition memory in mice by activating extracellular signal-regulated kinase 1/2.

  The Journal of pharmacology and experimental therapeutics 20070201

• Effects of a novel cognitive enhancer, spiro[imidazo-[1,2-a]pyridine-3,2-indan]-2(3H)-one (ZSET1446), on learning impairments induced by amyloid-beta1-40 in the rat.

  The Journal of pharmacology and experimental therapeutics 20060601

• Antiamnesic effects of azaindolizinone derivative ZSET845 on impaired learning and decreased ChAT activity induced by amyloid-beta 25-35 in the rat.

  Brain research 20020802

• Ameliorative effects of azaindolizinone derivative ZSET845 on scopolamine-induced deficits in passive avoidance and radial-arm maze learning in the rat.

  Japanese journal of pharmacology 20011101